Iterum Therapeutics plc (NASDAQ:ITRM) Short Interest Update

Iterum Therapeutics plc (NASDAQ:ITRM) saw a large increase in short interest during the month of November. As of November 15th, there was short interest totalling 2,740,000 shares, an increase of 8.3% from the October 31st total of 2,530,000 shares. Currently, 10.3% of the company’s shares are short sold. Based on an average daily volume of 2,480,000 shares, the short-interest ratio is presently 1.1 days.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and issued a $5.00 price target on shares of Iterum Therapeutics in a research note on Tuesday, September 10th.

Institutional Investors Weigh In On Iterum Therapeutics

A hedge fund recently bought a new stake in Iterum Therapeutics stock. XTX Topco Ltd acquired a new stake in Iterum Therapeutics plc (NASDAQ:ITRM) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 33,040 shares of the company’s stock, valued at approximately $36,000. XTX Topco Ltd owned 0.15% of Iterum Therapeutics at the end of the most recent quarter. 9.21% of the stock is owned by institutional investors and hedge funds.

Iterum Therapeutics Stock Performance

ITRM opened at $2.39 on Tuesday. Iterum Therapeutics has a 1 year low of $0.81 and a 1 year high of $2.42. The stock’s 50 day simple moving average is $1.31 and its 200 day simple moving average is $1.26.

Iterum Therapeutics Company Profile

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.